An interventional study of Ubiquinol 100 MG Oral Capsule and Placebo in Obesity & Overweight, GLP - 1 and Fatigue Severity Scale, sponsored by StudySetGo. Recruiting at 1 site in United Kingdom. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by StudySetGo · Not applicable, Interventional, and Basic science
The goal of this clinical trial is to learn if a daily ubiquinol supplement can reduce fatigue and help maintain muscle strength in adults aged 30-65 who are taking a GLP-1 weight loss medication (Wegovy® or Mounjaro®). Ubiquinol is a form of Coenzyme Q10 (CoQ10), a substance the body makes naturally that plays a key role in energy production. The main questions it aims to answer are:
Does ubiquinol lower fatigue levels compared to a placebo (a look-alike capsule that contains no ubiquinol)? Does ubiquinol help maintain muscle strength during weight loss treatment?
Researchers will compare ubiquinol to a placebo to see if ubiquinol helps with fatigue and muscle strength in people using GLP-1 medications.
Participants will:
Take one ubiquinol (100 mg) or placebo capsule every day for 9 months Have a nurse visit their home 4 times (at months 0, 3, 6, and 9) to take a small blood sample, measure their body, and supervise a simple sit-to-stand exercise test. Attend a short monthly video call (about 20-30 minutes) with a study dietitian. Complete questionnaires and 4 days of diet logging every 3 months using a smartphone app. Log all exercise sessions in the smartphone app throughout the study.
This is a fully remote study - participants do not need to visit a clinic. About 90 people will take part.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 90 is above the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →StudySetGo is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 19, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Ubiquinol 100 MG Oral Capsule
Dietary Supplement: Placebo
The active intervention is a commercially available ubiquinol dietary supplement. The dose is one 100mg capsule per day taken.
The placebo is manufactured by the same manufacturer that produces the active product. The placebo is visually similar to the active product and will be packaged in the same bottles as the active intervention to maintain the blind. The dose is one 100mg capsule per day taken with the first meal of the day. The product is stored at room temperature.
Self-reported fatigue
Measured via Chalder Fatigue Scale score
Time frame: 9 months
Quality of life questionnaire
Measured via WHOQoL-BREF
Time frame: 9 months
Skeletal muscle function
Measured via 5 x sit-to-stand test
Time frame: 9 months
Body Mass
Body Mass measured in kg
Time frame: 9 months
Blood pyruvate levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Time frame: 9 months
Blood Lactate levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Time frame: 9 months
Blood Coenzyme Q10 levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Time frame: 9 months
Blood Creatine Kinase levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Time frame: 9 months
Blood Vitamin D levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Time frame: 9 months
Blood Ferritin levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Time frame: 9 months
Blood Magnesium levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Time frame: 9 months
Blood Total Cholesterol levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Time frame: 9 months
Blood LDL levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Time frame: 9 months
Blood HDL levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Time frame: 9 months
Blood Triglycerides levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Time frame: 9 months
Blood Vitamin B12 levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Time frame: 9 months
Blood HBA1C levels
At each sampling timepoint, approximately 8 mL of blood will be drawn from the antecubital vein. Blood sampling, processing and analysis is managed by a third party company, following their own standard operating procedures.
Time frame: 9 months
Height
Measured in metres
Time frame: 9 months
Body Mass Index
Measured in kg/m²
Time frame: 9 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.
Of 3,680 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 15 months is below that.
Counting every sponsor, half of 3,843 studies reached it within 22 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ubiquinol
StudySetGo